Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from ZYUS Life Sciences ( (TSE:ZYUS) ) is now available.
ZYUS Life Sciences Corporation announced the closing of the first tranche of a non-brokered private placement, raising approximately $1,250,000.50 through the issuance of 1,923,077 units, each comprising one common share and one purchase warrant. The proceeds will be used for general corporate and working capital purposes. Additionally, the company issued warrants related to previously announced loans and a promissory note amendment, which have been approved by the TSX Venture Exchange. These transactions are classified as related party transactions under Multilateral Instrument 61-101.
The most recent analyst rating on (TSE:ZYUS) stock is a Buy with a C$1.50 price target. To see the full list of analyst forecasts on ZYUS Life Sciences stock, see the TSE:ZYUS Stock Forecast page.
More about ZYUS Life Sciences
ZYUS Life Sciences Corporation is a Canadian-based life sciences company that focuses on developing and commercializing novel cannabinoid-based pharmaceutical drug candidates for pain management. The company emphasizes rigorous scientific exploration and clinical research to secure intellectual property protection for its innovative therapies.
Average Trading Volume: 11,321
Technical Sentiment Signal: Sell
Current Market Cap: C$47.35M
Learn more about ZYUS stock on TipRanks’ Stock Analysis page.